Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People in JumpstART achieved viral suppression three times faster than those in the control group.
Starting antiretroviral therapy very early shrinks the latent viral reservoir and improves the prospects for attaining a functional cure.
Lenacapavir, a twice-yearly injectable, suppresses viral load in people with highly resistant virus.
These encouraging results do not apply, however, to people who remain undiagnosed.
Differences in HIV viral suppression between Black and white people have little to do with their personal behavior.
If at first you don’t reach an undetectable viral load, try, try again.
Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.
The funding will help address racial and ethnic disparities by supporting the federal “Ending the HIV Epidemic” plan.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
People who started treatment on the same day as their HIV diagnosis achieved an undetectable viral load sooner.
Low-barrier care and access to multiple services in one place can improve outcomes for people experiencing homelessness or unstable housing.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
Better integration and transition planning was associated with higher rates of viral suppression among youth with HIV.
UPDATE: Data from 2019 and 2020 have been added to America’s HIV Epidemic Analysis Dashboard (AHEAD), an interactive digital map.
Study finds that Cabenuva administered every other month maintains viral suppression for two years.
An HIV clinic saw a 31% lower likelihood of viral suppression after transitioning to telehealth due to COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.